Mechanisms of the pathogenesis of troponin T-based familial hypertrophic cardiomyopathy

Trends in Cardiovascular Medicine

Volumn 13, Issue 6, 2003, Pages 232-237

  Maass, Alexander H ^a   Leinwand, Leslie A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN T;

EXERCISE; FAMILIAL DISEASE; FIBROSIS; GENE IDENTIFICATION; GENE MUTATION; HEART DEATH; HEART MUSCLE CELL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SYSTOLE; TRANSGENIC MOUSE;

EID: 0041559840     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(03)00100-2     Document Type: Review

References (55)

1. Belardinelli R., Georgiou D., Cianci G., Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure. Effects on functional capacity, quality of life, and clinical outcome. Circulation. 99:1999;1173-1182.
2. Bonne G., Carrier L., Richard P.et al. Familial hypertrophic cardiomyopathy - from mutations to functional defects. Circ Res. 83:1998;580-593.
3. Bueno O.F., DeWindt L.J., Tymitz K.M.et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:2000;6341-6350.
4. 2+ activation of myofilaments from a transgenic mouse expressing R92Q mutant cardiac troponin T. Am J Physiol. 280:2001;H705-H713.
5. Ciampi Q., Betocchi S., Lombardi R.et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol. 40:2002;278-284.
6. Coats A.J.S., Adamopoulos S., Meyer T.E.et al. Effects of physical training in chronic heart failure. Lancet. 335:1990;63-66.
7. Cripps R.M., Olson E.N. Control of cardiac development by an evolutionarily conserved transcriptional network. Dev Biol. 246:2002;14-28.
8. de Tombe P.P., Solaro R.J. Integration of cardiac myofilament activity and regulation with pathways signaling hypertrophy and failure. Ann Biomed Eng. 28:2000;991-1001.
9. De Windt L.J., Lim H.W., Bueno O.F.et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 98:2001;3322-3327.
10. 2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. 106:2000;1351-1359.
11. Georgiou D., Chen Y., Appadoo S.et al. Cost-effectiveness analysis of long-term moderate exercise training on chronic heart failure. Am J Cardiol. 87:2001;984-988.
12. Gruver C.L., DeMayo F., Goldstein M.A., Means A.R. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology. 133:1993;376-388.
13. Han J., Molkentin J.D. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc Med. 10:2000;19-22.
14. Ho C., Lever H., DeSanctis R.et al. Homozygous mutation in cardiac troponin T. implications for hypertrophic cardiomyopathy Circulation. 102:2000;1950-1955.
15. Hunter J.J., Tanaka N., Rockman H.A.et al. Ventricular expression of an MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 270:1995;23,173-23,178.
16. Jackson T., Allard M.F., Sreenan C.M.et al. Transgenic animals as a tool for studying the effect of the c-myc proto-oncogene on cardiac development. Mol Cell Biochem. 104:1991;15-19.
17. Kai H., Muraishi A., Sugiu Y.et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 83:1998;594-601.
18. Kamisago M., Sharma S., DePalma S.et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 343:2000;1688-1696.
19. Kitabwalla M., Ruprecht R.M. RNA interference - a new weapon against HIV and beyond. N Engl J Med. 347:2002;1364-1367.
20. Knollmann B.C., Potter J.D. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med. 11:2001;206-212.
21. Liang Q., Molkentin J.D. Divergent signaling pathways converge on GATA4 to regulate cardiac hypertrophic gene expression. J Mol Cell Cardiol. 34:2002;611-616.
22. Liang Q., DeWindt L.J., Witt S.A.et al. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem. 276:2001;30,245-30,253.
23. Lu J., McKinsey T.A., Nicol R.L., Olson E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA. 97:2000;4070-4075.
24. Maass A., Leinwand L.A. Animal models of familial hypertrophic cardiomyopathy. Curr Opin Cardiol. 15:2000;189-196.
25. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 355:2000;58-60.
26. Maron B.J. Hypertrophic cardiomyopathy. Lancet. 350:1997;127-133.
27. Maron B.J., Gardin J.M., Flack J.M.et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of. 4111(subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 92):1995;785-789.
28. Maron B.J., Shirani J., Poliac L.C.et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 276:1996;199-204.
29. McKinsey T.A., Zhang C.L., Lu J., Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 408:2000;106-111.
30. Minamino T., Yujiri T., Terada T.et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci. 99:2002;3866-3871.
31. Molkentin J.D., Markham B.E. Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo. J Biol Chem. 268:1993;19,512-19,520.
32. Molkentin J.D., Lu J.R., Antos C.L.et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
33. Nagata M., Shimizu M., Ino H.et al. Hemodynamic changes and prognosis in patients with hypertrophic cardiomyopathy and abnormal blood pressure responses during exercise. Clin Cardiol. 26:2003;71-76.
34. Naya F.J., Wu C., Richardson J.A.et al. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development. 126:1999;2045-2052.
35. Oberst L., Zhao G., Park J.T.et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest. 102:1998;1498-1505.
36. Olivotto I., Cecchi F., Casey S.A.et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 104:2001;2517-2524.
37. Passier R., Zheng H., Frey N.et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest. 105:2000;1395-1406.
38. Ritter O., Hack S., Schuh K.et al. Calcineurin in human heart hypertrophy. Circulation. 105:2002;2265-2269.
39. Roberts R., Sigwart U. New concepts in hypertrophic cardiomyopathy, part I. Circulation. 104:2001;2113-2116. a.
40. Roberts R., Sigwart U. New concepts in hypertrophic cardiomyopathy, part II. Circulation. 104:2001;2249-2252. b.
41. Semsarian C., Healey M.J., Fatkin D.et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 33:2001;2055-2060.
42. Semsarian C., Ahmad I., Giewat M.et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 109:2002;1013-1020.
43. Shamim W., Yousufuddin M., Wang D.et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med. 347:2002;1326-1333.
44. Solaro R.J., Rarick H.M. Troponin and tropomyosin. proteins that switch on and tune in the activity of cardiac myofilaments Circ Res. 83:1998;471-480.
45. Solaro R.J., Varghese J., Marian A.J., Chandra M. Molecular mechanisms of cardiac myofilament activation. modulation by pH and a troponin mutant R92Q Basic Res Cardiol. 97:2001;I102-I110.
46. Spirito P., Bellone P., Harris K.M.et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 342:2000;1778-1785.
47. Sussmann M.A., Lim H.W., Gude N.et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
48. Suzuki M., Carlson K.M., Marchuk D.A., Rockman H.A. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation. 105:2002;1824-1829.
49. Swynghedauw B. Developmental and functional adaptations of contractile proteins in cardiac and skeletal muscles. Physiol Rev. 66:1986;710-771.
50. Tardiff J.C., Factor S.M., Tompkins B.D.et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest. 101:1998;2800-2811.
51. Tardiff J.C., Hewett T.E., Palmer B.M.et al. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest. 104:1999;469-481.
52. Van Driest S.L., Ackerman M.J., Ommen S.R.et al. Prevelance and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 106:2002;3085-3090.
53. Varnava A.M., Elliott P.M., Baboonian C.et al. Hypertrophic cardiomyopathy - histopathological features of sudden cardiac death in cardiac troponin T disease. Circulation. 104:2001;1380-1384.
54. Wigle E.D., Rakowski H., Kimball B.P., Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 92:1995;1680-1692.
55. Wu H., Kanatous S.B., Thurmond F.A.et al. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science. 296:2002;349-352.